(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of 25.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Ptc Therapeutics's revenue in 2026 is $827,110,000.On average, 16 Wall Street analysts forecast PTCT's revenue for 2026 to be $99,622,154,938, with the lowest PTCT revenue forecast at $87,760,399,604, and the highest PTCT revenue forecast at $121,603,729,508. On average, 16 Wall Street analysts forecast PTCT's revenue for 2027 to be $113,059,947,694, with the lowest PTCT revenue forecast at $89,253,487,688, and the highest PTCT revenue forecast at $167,640,612,098.
In 2028, PTCT is forecast to generate $136,119,863,658 in revenue, with the lowest revenue forecast at $98,958,560,234 and the highest revenue forecast at $204,967,814,198.